Tianjin Medical University Cancer Institute and Hospital
A randomised controlled trial of vinorelbine plus capecitabine versus docetaxel plus capecitabine in anthracycline-pretreated women with metastatic breast cancer. The primary endpoints of the study is progression free survival (PFS). The secondary endpoints are overall response rate (ORR), overall survival (OS) and safety.
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
female ≥ 18 years old ECOG 0-2
You may not be if
brain metastasis
Clareo Health | Vinorelbine Plus Capecitabine Versus Docetaxel Plus Capecitabine in Anthracycline-pretreated Women With Metastatic Breast Cancer
